On July 23, 2025, Humacyte, Inc. announced the first sale of Symvess to a U.S. Military Treatment Facility. This sale follows the recent Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency, which made Symvess available to federal healthcare providers.
The military facility is a state-of-the-art medical complex serving approximately 200,000 active-duty service personnel, retirees, and their families. This initial purchase signifies the beginning of Symvess's adoption within the Department of Defense and U.S. Department of Veterans Affairs healthcare systems.
Symvess, approved by the FDA in December 2024 for extremity vascular trauma, is now accessible to healthcare professionals at approximately 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals. This first sale is a tangible step in expanding the product's commercial reach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.